PAM
MITO

PVG Asset Management’s Stealth BioTherapeutics Corp. ADS MITO Stock Holding History

PVG Asset Management’s Portfolio MITO Stock Details MITO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-11,988
Closed -$18.7K – 78
2021
Q2 		$18.7K Buy
+11,988
New +$16.7K 0.06% 53

Other funds holding MITO

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BBHC
Brown Brothers Harriman & Co New York $22.8B AUM 25.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
SBL
Sargent Bickham Lagudis Boulder, Colorado $1.22B AUM 14.94% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PVG Asset Management's MITO Position: Q3 2021 in Review

PVG Asset Management sold out of Stealth BioTherapeutics Corp. ADS (MITO) in Q3 2021, closing a stake of 11,988 shares — an estimated $18.7K sold.

PVG Asset Management first reported a position in MITO in Q2 2021 and held it in 1 quarter. The position peaked at $18.7K in Q2 2021. 14 funds tracked by Wall St. Rank hold MITO as of Q3 2021.

  • PVG Asset Management reported no remaining Stealth BioTherapeutics Corp. ADS position as of Q3 2021 after selling out during the quarter.
  • PVG Asset Management sold 11,988 Stealth BioTherapeutics Corp. ADS shares in Q3 2021, an estimated $18.7K.
  • PVG Asset Management first reported a position in Stealth BioTherapeutics Corp. ADS in Q2 2021 and held it in 1 quarter.
  • PVG Asset Management's Stealth BioTherapeutics Corp. ADS position peaked at $18.7K in Q2 2021.
  • 14 funds tracked by Wall St. Rank held Stealth BioTherapeutics Corp. ADS as of Q3 2021.

Based on PVG Asset Management's 13F filing for Q3 2021, filed 10 Nov 2021.